{
    "nct_id": "NCT04513925",
    "official_title": "A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Histologically or cytologically documented NSCLC with locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology\n* Whole-body Positron Emission Tomography-Computed Tomography (PET-CT) scan, performed prior and within 42 days of the first dose of concurrent chemoradiotherapy (cCRT)\n* At least two prior cycles of platinum-based chemotherapy administered concurrently with radiotherapy (RT), which must be completed within 1 to 42 days prior to randomization in the study (one cycle of cCRT is defined as 21 or 28 days)\n* The radiotherapy (RT) component in the cCRT must have been at a total dose of radiation of 60 (Â±10 percent [%]) gray (Gy) (54 Gy to 66 Gy) administered by intensity modulated RT (preferred) or 3D-conforming technique\n* No progression during or following concurrent platinum-based CRT\n* A known PD-L1 result\n* Life expectancy >/= 12 weeks\n* Adequate hematologic and end-organ function\n* Female participants must be willing to avoid pregnancy for 90 days after the final dose of tiragolumab and 5 months after the final dose of atezolizumab, or for 3 months after the final dose of durvalumab\n* Male participants must remain abstinent or use a condom during the treatment period and for 90 days after the final dose of tiragolumab\n* Male participants must not donate sperm during the treatment period and for 90 days after the final dose of tiragolumab\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any history of prior NSCLC and/or any history of prior treatment for NSCLC (participants must be newly diagnosed with unresectable Stage III disease)\n* NSCLC known to have a mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) fusion oncogene\n* Any evidence of Stage IV disease\n* Treatment with sequential CRT for locally advanced NSCLC\n* Participants with locally advanced NSCLC who have progressed during or after the definitive cCRT prior to randomization\n* Any Grade >2 unresolved toxicity from previous CRT\n* Grade >= 2 pneumonitis from prior CRT\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis or evidence of active pneumonitis\n* History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with a negligible risk of metastasis or death\n* Prior allogeneic stem cell or solid organ transplantation\n* Active Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection at screening\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated protein 4, anti-T-cell immunoreceptor with Ig and ITIM domains (anti-TIGIT), anti-PD-1 and anti-PD-L1\n* Any prior Grade >/= 3 immune-mediated adverse event or any unresolved Grade > 1 immune-mediated adverse event while receiving any previous immunotherapy agent other than immune checkpoint blockade agents\n* Treatment with systemic immunosuppressive medication\n* Women who are pregnant, or breastfeeding",
    "miscellaneous_criteria": ""
}